ABSTRACT To investigate whether ergonovine acts directly on coronary arteries or via remote neurohumoral reflexes, we administered small titrated increments of intracoronary ergonovine up to a maximum cumulative dose of 50 gg to 15 patients. In six patients with variant angina (group 1), ischemic electrocardiographic ST changes, angina, and localized coronary spasm (local coronary diameter reduction of 87.8 18.9% [mean ± SD]) followed after 6 to 50 g£g (mean 20.7) cumulative intracoronary ergonovine. In nine patients with atypical chest pain, normal baseline coronary arteriograms, and no evidence of variant angina (group 2), there was no ischemic ST segment change or localized coronary spasm after 6 to 50 ug (mean 31.6) intracoronary ergonovine. Coronary diameter of proximal vessels of patients in group 2 was reduced by 16.2 ± 6.5% and did not differ from the response of nonspastic vessels of comparable size of group 1 (20.5 13.8%; p = .7). There was no significant difference in the median effective dose values in the dose-response curves of the spastic and nonspastic segments between groups 1 and 2. Ergonovine causes coronary spasm by a direct local effect, which seems to be caused by localized arterial hyperreactivity rather than supersensitivity. Intracoronary delivery may be safer than intravenous administration because negligible drug recirculation may prevent perpetuation of spasm and selective coronary administration can avoid branches with critical stenoses. Circulation 75, No. 3, 577-582, 1987. THE ETIOLOGY of coronary artery spasm remains unclear.' A wide variety of provocations can induce spasm in susceptible patients, including such stimuli as hyperventilation, cold pressor, and exercise as well as agents such as ergonovine,2' 3 histamine,4 and dopamine.' However, specific antagonists of receptors possibly involved in the pathogenesis of spasm have failed to consistently prevent coronary spasm in vivo.6-Ergonovine is the most commonly used and most powerful agent for provoking coronary spasm in vivo,9' 10 but the drug has a relatively weak action on isolated human epicardial coronary artery rings in vitro." Spasm usually appears several minutes after administration of ergonovine, but whether this delay is caused by local or systemic factors is unknown. Therefore we undertook a study of the effects of direct intracoronary administration of titrated increments of er- March 1987 gonovine to investigate whether the mechanism of action of the drug is local or systemic. This method of administration, by resulting in a large systemic dilution of the drug, should have the advantage of avoiding both systemic neurohumeral reflexes and side effects.
THE ETIOLOGY of coronary artery spasm remains unclear.' A wide variety of provocations can induce spasm in susceptible patients, including such stimuli as hyperventilation, cold pressor, and exercise as well as agents such as ergonovine,2' 3 histamine,4 and dopamine.' However, specific antagonists of receptors possibly involved in the pathogenesis of spasm have failed to consistently prevent coronary spasm in vivo. 6- Ergonovine is the most commonly used and most powerful agent for provoking coronary spasm in vivo,9' 10 but the drug has a relatively weak action on isolated human epicardial coronary artery rings in vitro." Spasm usually appears several minutes after administration of ergonovine, but whether this delay is caused by local or systemic factors is unknown. Therefore we undertook a study of the effects of direct intracoronary administration of titrated increments of er-gonovine to investigate whether the mechanism of action of the drug is local or systemic. This method of administration, by resulting in a large systemic dilution of the drug, should have the advantage of avoiding both systemic neurohumeral reflexes and side effects.
Patients and methods
We studied 15 patients undergoing diagnostic cardiac catheterization. Six patients had a typical history of variant angina pectoris, with continuing active symptoms at the time of investigation (group 1). Three patients had coronary stenoses varying from 17% to 55% luminal narrowing, and the three other patients had no fixed stenoses in the spastic segments. Except for one patient (No. 2) who had had an inferolateral myocardial infarction 6 months earlier and an occluded right coronary artery, no other coronary stenoses were evident. An intravenous ergonovine test with incremental doses of 25 to 300 pug of ergonovine, performed before cardiac catheterization in the noninvasive laboratory with 12 lead electrocardiographic monitoring, was positive in all six patients with chest pain and electrocardiographic signs of ischemia, which promptly resolved after 2 to 5 mg of intravenous isosorbide dinitrate.
The nine control patients (group 2) were investigated for "atypical" chest pain. One patient (No. 8) had had documented variant angina pectoris at coronary arteriography 2 years earlier but had been completely free of symptoms without medical therapy for over 1 year. None of the other eight patients had a history typical of variant angina pectoris. All nine had normal 577 After diagnostic coronary arteriography using the Judkins technique, an appropriate view of the relevant coronary artery was selected and a control arteriogram was obtained. The artery was chosen on the basis of previous regional electrocardiographic localization of myocardial ischemia during chest pain in group 1. In group 2 ergonovine was administered to the left coronary artery in six and to the right in three patients. Ergonovine was administered by slow intracoronary injection over 1 min of titrated increments of 1, 5, 10, and 30 gg diluted in volumes of 5 to 10 ml of normal saline. The maximum cumulative dose used was 50 ,gg. A minimum time of 5 min was allowed to elapse between increments during which anterior and inferior ECG monitoring and recording were continued. Patients were asked to report the onset of any chest pain and, if indicated by either pain or ECG changes, coronary arteriography was performed. Coronary arteriography was performed after each increment of ergonovine and after administration of 2 mg of intracoronary isosorbide dinitrate. Care was taken that the rotation and skew angles, height, and magnification factors of the x-ray image intensifier were not altered during the study so that comparable arteriograms were obtained before, during, and after provocation. 1 ,g (range 6 to 50) of ergonovine but not after the same volume of intracoronary saline or radiographic contrast medium in all. The chest pain in these five patients was relieved promptly after administration of 2 mg of intracoronary isosorbide dinitrate. The degree of localized reduction of luminal diameter of the spastic segments was 1.63 ± 0.4 mm, significantly greater than the generalized constriction of the nonspastic vessels of group 1 (0.51 ± 0.6 mm; p = .007) or of the generalized change of those vessels of group 2 (0.40 ± 0.1 mm; p = .0008) (see table 3 and figures 1 and 2). There was no significant difference in the reduction of coronary caliber between the nonspastic vessels of group 1 and group 2 (p = .7). There were no significant changes in heart rate or blood pressure after intracoronary ergonovine, and no side effects were observed or reported by the patients.
The dose-response relationship is illustrated in figure showing spasm both in the patients with (20.5 t 13.8%; p .0001) and those without (16.2 + 6.5%; p = .0003) variant angina ( figure 3) . However, the constrictor response to ergonovine occurred over the same dose range whether or not spasm resulted. The median effective dose (ED50) value for the induction of maximal spasm was 4.70 ± 5.9 gg, not significantly different from the EDSO of group 2 (4.05 ± 2.2 gg; p .8).
Discussion
This study demonstrates that ergonovine induces coronary artery spasm by a direct local coronary mechanism. Intracoronary doses as low as 6 gg provoked spasm in four patients, much less than 5% of the usually effective intravenous doses. Spasm appeared I to 3 min after intracoronary administration of the drug, a delay similar to that observed after intravenous administration. Systemic dilution of intracoronary doses results in a very low recirculating concentration most unlikely to have elicited any systemic neurohumoral reflexes, but confirmation of this would have required repeated cardiac catheterization. Finally, the magnitude of the coronary constrictor and dilator responses of the spastic and nonspastic segments was similar to that previously reported after intravenous administration of ergonovine. '2 13 In those patients with the most typical syndrome of variant angina, coronary spasm induced by intracoronary ergonovine was limited to one coronary artery segment, with the other vessels exhibiting a "normal physiologic" constrictor response. Whether the spastic 580 response was elicited by direct contact of ergonovine with the intima or by direct action on the smooth muscle or perivascular neural plexus via the vasa vasorum remains to be elucidated.
The dose-response relationship of ergonovine (figure 3) shows that both local coronary spasm and generalized vasoconstriction occurred over the same range of doses both in the same patients and in the control subjects. This finding suggests that in those patients with variant angina, the spasm provoked by ergonovine is caused by a local hyperreactivity rather than a supersensitivity characterized by a displacement of the dose-response curve to the left. 14 The clear difference in the magnitude of the effect of ergonovine on spastic and nonspastic coronary segments supports the view that complete or almost complete local occlusion characterizes the spastic response in contrast to normal ";physiologic" vasoconstriction. '5 This study also provides evidence that chest pain occurring after intravenous administration of ergonovine may not necessarily be caused by esophageal spasm.'6 17 Chest pain in three patients occurred after doses as low as 6 gg of intracoronary ergonovine (but not reproduced after an equivalent volume of intracoronary saline or radiographic contrast medium), suggesting that the pain is indeed coming from the heart and not from the esophagus. It is possible that in these patients ergonovine caused chest pain by inducing constriction of small coronary vessels with a reduced vasodilator reserve. '8 The intracoronary route of administration of ergonovine may be safer than the intravenous route, since the CIRCULATION negligible recirculation should avoid any perpetuation of coronary spasm and when desirable its effect on coronary arteries with critical stenoses can be avoided. This diagnostic technique may also be used when intravenous ergonovine is otherwise contraindicated, for example in the presence of transient ischemic attacks of the central nervous system. 
